Cancer cell diagnosis by targeting delivery of nanodevices

Details Cancer cell diagnosis by targeting delivery of nanodevices Cancer cell diagnosis by targeting delivery of nanodevices

2011-07-12

2011-07-12

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Magnetic imaging agent

C424S009350, C424S009430, C424S493000, C424S497000, C424S499000, C977S773000, C977S930000

Reexamination Certificate

active

07976825

ABSTRACT:
Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of chitosan (CHIT) as polycation and poly-gamma glutamic acids (PGA) as polyanion. NP's are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid (FA) is linked to the NP's to produce NP-FA bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line.

REFERENCES:
patent: 5820851 (1998-10-01), Peng et al.
patent: 7291598 (2007-11-01), Sung et al.
patent: 2005/0226938 (2005-10-01), Borbely et al.
patent: 2008/0160096 (2008-07-01), Berbely et al.
patent: WO 00/66090 (2000-11-01), None
patent: WO 2004096998 (2004-11-01), None

Affiliated with

Also associated with

Rating

Cancer cell diagnosis by targeting delivery of nanodevices does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer cell diagnosis by targeting delivery of nanodevices, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer cell diagnosis by targeting delivery of nanodevices will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680444